Exhibit 10.4
ATLANTIC Technology Ventures, Inc.
The Empire State Building
000 Xxxxx Xxxxxx
Xxxxx 0000
Xxx Xxxx, XX 00000
Telephone: 000.000.0000
Fax: 000.000.0000
xxx.xxxxx.xxx
-------------
January 10, 2003
Xx. Xxxxxxxx Xxxxxxxx
Xx. Xxxxxx Xxxx
Xx. Xxxxxx Xxxxx
Institute for Hygiene and Social Medicine
University of Innsbruck
Xxxxx Xxxxx Xxxxxxx 0
X-0000, Xxxxxxxxx
XXXXXXX
Re: Assignment of October 18, 2001 License Agreement
Concerning N-Chlorotaurine
Gentlemen:
As we have discussed, Atlantic Technology Ventures, Inc. desires to assign
all of its rights and obligations under the October 18, 2001 License Agreement
to Pathogenics, LLC a new corporate entity to be owned by Xxxxxxxx X. Xxxxx, A.
Xxxxxx Xxxxxx, and Xxxxxxx X. Xxxxxxx.
Article 9 of the abovementioned October 18, 2001 License Agreement provides
as follows:
"This Agreement, the Patent Rights and the other rights and duties
appertaining hereto may not be assigned by either party without first
obtaining the written consent of the other which shall not otherwise be
unreasonably withheld."
I ask that you indicate your consent to Atlantic's assignment of its rights
and obligations under the License Agreement by countersigning this letter, as
indicated below.
With best regards,
/s/ Xxxxxxxx X. Xxxxx
Xxxxxxxx X. Xxxxx, Esq.
President & CEO
Atlantic Technology Ventures, Inc.
Page 1 of 2
AGREED AND ACCEPTED
By: /s/ Xx. Xxxxxxxx Xxxxxxxx
------------------------
Xx. Xxxxxxxx Xxxxxxxx
By: /s/ Xx. Xxxxxx Xxxx
------------------------
Xx. Xxxxxx Xxxx
By: /s/ Xx. Xxxxxxx Xxxxx
------------------------
Xx. Xxxxxxx Xxxxx
Page 2 of 2
